Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients

被引:31
作者
Viscoli, C
Paesmans, M
Sanz, M
Castagnola, E
Klastersky, J
Martino, P
Glauser, M
机构
[1] Ist Nazl Ric Canc, I-16132 Genoa, Italy
[2] Univ Genoa, Genoa, Italy
[3] G Gaslini Inst Children, Genoa, Italy
[4] Univ Roma La Sapienza, Rome, Italy
[5] Inst Jules Bordet, B-1000 Brussels, Belgium
[6] Univ Valencia, La Fe Univ Hosp, Valencia, Spain
[7] CHU Vaudois, CH-1011 Lausanne, Switzerland
关键词
D O I
10.1086/320514
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Published data have suggested a correlation between antifungal prophylaxis and bacteremia in febrile neutropenia. This correlation was investigated among 3002 febrile neutropenic patients enrolled in 4 trials during 1986-1994. Globally, 1322 patients (44%) did not receive antifungal prophylaxis; 835 (28%) received poorly absorbable antifungal agents and 845 (28%) received absorbable antifungal agents. The rates of bacteremia for these groups were 20%, 26%, and 27%, respectively (P = .0001). In a multivariate model without including antifungal prophylaxis, factors associated with bacteremia were: age, duration of hospitalization, duration of neutropenia before enrollment, underlying disease, presence of an intravenous catheter, shock, antibacterial prophylaxis, temperature, and granulocyte count at onset of fever. When antifungal prophylaxis was included, the adjustment quality of the model improved slightly (P = .05), with an odds ratio of 1.19 (95% confidence interval [CI], 0.92- 1.55) for patients receiving nonabsorbable and 1.42 (95% CI, 1.07- 1.88) for those who were receiving absorbable antifungal agents. Antifungal prophylaxis with absorbable agents might have an impact on the rate of documented bacteremia in febrile neutropenia. This effect should be confirmed prospectively.
引用
收藏
页码:1532 / 1537
页数:6
相关论文
共 17 条
  • [1] [Anonymous], 1991, J Infect Dis, V163, P951
  • [2] CALANDRA T, 1987, NEW ENGL J MED, V317, P1692
  • [3] EFFICACY AND TOXICITY OF SINGLE DAILY DOSES OF AMIKACIN AND CEFTRIAXONE VERSUS MULTIPLE DAILY DOSES OF AMIKACIN AND CEFTAZIDIME FOR INFECTION IN PATIENTS WITH CANCER AND GRANULOCYTOPENIA
    CALANDRA, T
    ZINNER, SH
    VISCOLI, C
    DEBOCK, R
    GAYA, H
    MEUNIER, F
    KLASTERSKY, J
    GLAUSER, MP
    NINOVE, D
    LANGENAEKEN, J
    PAESMANS, M
    GALAZZO, M
    GIDDEY, M
    BILLE, J
    HADJDJILANI, A
    MASSIMO, L
    MORONI, C
    CASTAGNOLA, E
    SANZ, M
    FERSTER, A
    DEBOCK, R
    MEUNIER, F
    KLASTERSKY, J
    PADMOS, A
    GALLAGHER, J
    COMETTA, A
    GLAUSER, MP
    CALANDRA, T
    LOPEZ, A
    MARTINEZDALMAU, A
    POGLIANI, E
    HEMMER, R
    DICATO, M
    RIES, F
    PORCELLINI, A
    LEGRAND, JC
    PORCELLINI, A
    ESTAVOYER, JM
    FOLLATH, F
    SEITANIDES, B
    ZINNER, S
    BROWNE, M
    NIKOSKELAINEN, J
    ROSSI, M
    MASERA, G
    [J]. ANNALS OF INTERNAL MEDICINE, 1993, 119 (07) : 584 - 593
  • [4] PIPERACILLIN-TAZOBACTAM PLUS AMIKACIN VERSUS CEFTAZIDIME PLUS AMIKACIN AS EMPIRIC THERAPY FOR FEVER IN GRANULOCYTOPENIC PATIENTS WITH CANCER
    COMETTA, A
    ZINNER, S
    DEBOCK, R
    CALANDRA, T
    GAYA, H
    KLASTERSKY, J
    LANGENAEKEN, J
    PAESMANS, M
    VISCOLI, C
    GLAUSER, MP
    GIBSON, B
    SANZ, M
    HANN, IM
    FOLLATH, F
    FATIO, R
    FERSTER, A
    VANHOOF, A
    VANLANDUYT, H
    ARENDT, V
    HEMMER, R
    PEETERMANS, M
    PADMOS, A
    SEITANIDES, B
    HATZIYANNI, M
    LOPEZ, A
    PORCELLINI, A
    GREK, V
    CABALLERO, D
    TOGNI, P
    GALLAGHER, JG
    GARAVENTA, A
    MASSIMO, L
    SUGAR, A
    LEGRAND, JC
    OPPENHEIM, B
    PETRIKKOS, G
    BEYTOUT, J
    NIKOSKELAINEN, J
    SHAPIRO, M
    ESTAVOYER, JM
    KERN, W
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (02) : 445 - 452
  • [5] Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer
    Cometta, AF
    Calandra, T
    Gaya, H
    Zinner, SH
    deBock, R
    DelFavero, A
    Bucaneve, G
    Crokaert, F
    Kern, WV
    Klastersky, J
    Langenaeken, J
    Micozzi, A
    Padmos, A
    Paesmans, M
    Viscoli, C
    Glauser, MP
    Martino, P
    Caballero, D
    Engelhard, D
    Shapiro, M
    Castagnola, E
    Massimo, L
    Giacchino, R
    Sanz, M
    Gigium, M
    Carotenuto, M
    Lopez, A
    Andrien, JM
    Paulus, R
    Martino, B
    Nobile, F
    Togni, P
    Ferster, A
    Cudillo, L
    Legrand, JC
    Dinota, A
    Cajozzo, A
    Quintini, G
    MartinezDalmau, A
    Nosari, A
    Bucaneve, GP
    Cometta, A
    Galazzo, M
    Giddey, M
    Bille, J
    Blaser, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (05) : 1108 - 1115
  • [6] PREVENTION OF BACTERIAL-INFECTION IN NEUTROPENIC PATIENTS WITH HEMATOLOGIC MALIGNANCIES - A RANDOMIZED, MULTICENTER TRIAL COMPARING NORFLOXACIN WITH CIPROFLOXACIN
    DELFAVERO, A
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (01) : 7 - 12
  • [7] A CONTROLLED TRIAL OF FLUCONAZOLE TO PREVENT FUNGAL-INFECTIONS IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION
    GOODMAN, JL
    WINSTON, DJ
    GREENFIELD, RA
    CHANDRASEKAR, PH
    FOX, B
    KAIZER, H
    SHADDUCK, RK
    SHEA, TC
    STIFF, P
    FRIEDMAN, DJ
    POWDERLY, WG
    SILBER, JL
    HOROWITZ, H
    LICHTIN, A
    WOLFF, SN
    MANGAN, KF
    SILVER, SM
    WEISDORF, D
    HO, WG
    GILBERT, G
    BUELL, D
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (13) : 845 - 851
  • [8] Kern W, 1998, CANCER-AM CANCER SOC, V83, P291, DOI 10.1002/(SICI)1097-0142(19980715)83:2&lt
  • [9] 291::AID-CNCR13&gt
  • [10] 3.3.CO